Weil represented WellSpring Consumer Healthcare, a portfolio company of Avista Capital Partners, in its acquisition of a portfolio of well-recognized and trusted over-the-counter skin care brands from Bayer AG. WellSpring Consumer Healthcare is a leading middle-market healthcare private equity firm with expertise in building OTC platforms.

The brands include A+D^®, a leading diaper rash and skin protectant brand; Solarcaine®, the leading sunburn relief brand; and Cortate^® and Complex 15^®, two Canadian therapeutic skincare brands. A+D^® is a widely recognized brand that has been endorsed by pediatricians and trusted by consumers for more than 80 years. Solarcaine^® is a pharmacist-recommended medicated burn relief brand that has been relied upon by consumers for generations.

The Weil team advising WellSpring Consumer Healthcare and Avista Capital Partners is led by Private Equity partner Brian Parness and includes Private Equity associates Hannah Schmitz and Jonas Mutukistna. The team also includes Tax partner Helyn Goldstein and Tax associates Greg Williamson and Griffin Baker; Banking partner Andrew Yoon and Banking associates Dylan Scher and Christopher Chan; Executive Compensation & Benefits partner Amy Rubin; Regulatory & Transactions Group partner John O’Loughlin and Regulatory & Transactions Group associate Christina Carone; Antitrust/Competition counsel Michael Naughton; Technology & IP Transactions partners Dennis Adams and Olivia Greer as well as Technology & IP Transactions associates Catherine Kim and Amy Montoya.